Malignant Neoplastic Disease clinical trials at UC Health
1 research study open to new patients

• MRTX849 in Patients With Cancer Having a KRAS G12C Mutation

  open to eligible people ages 18 years and up

  Evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

  at UC Irvine

Last updated: January 22, 2019